Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study)

Table 1 Demographics, clinical baseline characteristics of the study populations

Parameter	Sub-parameter	Immediate treatment	Deferred treatment	p-value (if applicable)
Age (mean ± SD) (years)		42.9 (± 8.6)	42 (± 10.4)	0.714
Gender-no./total-no. (%)	Male	29/31 (93.5)	27/30 (90.0)	0.671
Gender-no./total-no. (%)	Female	2/31 (6.5)	3/30 (10.0)	0.671
Race-no./total no. (%)	White	28/31 (90.3)	26/30 (86.7)	0.833
Race-no./total no. (%)	Black-African	3/31 (9.7)	4/30 (13.3)	0.833
Viral load before randomization	Mean (cop/mL)	447,579	570,020
CD4 cells before randomization (baseline)	Mean (absolute)	27	42
PCP (n = number of patients)		24	26
TE (n = number of patients)		7	4

ISSN: 1742-6405